Trials / Recruiting
RecruitingNCT04312399
Hormone Replacement Trial Against ALzheimers' Disease
- Status
- Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 600 (estimated)
- Sponsor
- University Hospital, Ghent · Academic / Other
- Sex
- Female
- Age
- 40 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
The influence of postmenopausal hormone treatment on dementia is not clear. Dysfunctions in the metabolism of amyloid in the disease of Alzheimer result in an elevated presence of degradation products in cerebrospinal fluid. The degradation products in blood will be analysed during the trial, to get better insight in menopause and the start of hormonal therapy. Postmenopausal women with and without history of breast cancer will be recruited for the trial.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | blood take | Blood is taken to analyse degradation products of the metabolism of amyloid |
Timeline
- Start date
- 2018-04-17
- Primary completion
- 2027-12-31
- Completion
- 2028-12-31
- First posted
- 2020-03-18
- Last updated
- 2025-01-27
Locations
1 site across 1 country: Belgium
Source: ClinicalTrials.gov record NCT04312399. Inclusion in this directory is not an endorsement.